Quell Therapeutics and Cellistic collaborate to develop T-regulatory cell therapy platform
pharmafile | April 27, 2022 | News story | Research and Development |
Quell Therapeutics and Cellistic have entered into a strategic collaboration for the co-development of an iPSC-derived Treg cell therapy platform.
Under the terms of the agreement, Quell and Cellistic will collaborate in joint research to develop a process for differentiating iPSCs into highly functional Treg cell therapy products. Quell will contribute its Treg expertise and engineering technologies, as well as characterising resulting Treg cells, while Cellistic will be responsible for the iPSC process science and development activities.
Iain McGill, CEO, Quell Therapeutics, said: “Quell has made significant progress advancing the first candidate from our autologous multi-modular Treg cell therapy platform into the clinic, with the initiation of our LIBERATE study of QEL-001 to prevent liver transplant rejection. We believe there is significant opportunity to transform outcomes for patients with QEL-001 and other autologous Treg cell therapy products in our pipeline.
“Our collaboration with Cellistic is a key building block in our investment towards a future, next-generation allogeneic Treg cell platform, which could significantly expand our opportunities to develop novel off-the-shelf treatments across a wide range of diseases driven by immune dysregulation. We highly respect the expertise and experience of Ncardia and the Cellistic team, and its track record in developing rapidly scalable iPSC cell therapy processes.”
Stefan Braam, CEO, Cellistic, said: “Our partnership with Quell is emblematic of why we started Cellistic – to bring together our focus and expertise in the development and implementation of iPSC cell therapy platforms with companies like Quell that have an equal depth of expertise in therapeutic development and share our vision for the future of cell therapy. We are excited to collaborate with the Quell team, both to develop the platforms, and to support Quell’s long-term supply needs as they deliver impactful therapeutics to patients.”
Lina Adams
